-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-517568-48-00
5
2025-07-21
Delayed Graft Function after Kidney Transplantation
-
2024-517789-41-00
6
2025-07-04
metastatic or locally advanced renal cell carcinoma
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-515214-41-00
5
2025-03-27
advanced pancreatic cancer
-
2024-519514-31-00
4
2025-01-31
metastatic triple-negative PD-L1 positive breast cancer
-
2024-517504-11-00
5
2025-01-29
Pregnant patients diagnosed with premature rupture of membranes (PROM)
-
2024-511945-20-00
4
2025-01-24
patients affected by small cell lung cancer (SCLC)
-
2024-514656-32-00
4
2025-01-23
Suspected or confirmed Gram negative infections
-
2023-509883-89-00
5
2025-01-09
Epidermal growth factor receptor (EGFR) mutation-positive, locally adv
-
2024-516842-21-00
5
2025-01-09
Recurrent ovarian cancer
-
2024-516450-21-00
6
2024-12-31
metastatic or locally advanced urothelial cancer
-
2024-519286-21-00
5
2024-12-17
MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2024-518092-62-00
5
2024-12-09
Adult critically ill patients requiring non-invasive (NIMV) or invasiv
-
2024-517863-22-00
5
2024-12-01
Study population consists in patients with a diagnosis of mCRC who hav
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-506632-32-00
5
2024-10-28
Metastatic colorectal cancer
-
2023-509851-15-00
5
2024-10-22
Colon cancer
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-507803-76-00
10
2024-09-26
Peripheral T-Cell Lymphoma
-
2023-504169-22-02
5
2024-07-31
Severe cardiac inflammation
-
2023-508178-27-00
9
2024-07-10
Participants with Advanced KRASG12C-Mutated Solid Tumors